Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. We believe that a healthy economy, environment and society are fundamental to long-term value creation. This is why we manage our business in accordance with the Triple Bottom Line business principle and consider the financial, environmental and social impact of our business decisions. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today's business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance.
POSTED
12-20-10
Novo Nordisk praises historic declaration to fight diabetes
On December 13, 2010, twenty-two countries from the Middle East and Northern Africa (MENA) and five international organisations agreed on the "Dubai Declaration on Diabetes and Chronic Non-Communicable Diseases in the Middle East and Northern Africa Region." The agreement wa...
POSTED
12-10-10
Novo Nordisk welcomes new guidelines on human rights
On the occasion of the 62nd anniversary, Novo Nordisk welcomes the Draft Guiding Principles presented by Professor John Ruggie, Special Representative to the UN Secretary General. The Ruggie's Guiding Principles elaborate and clarify for companies, states, and other stakehol...
POSTED
10-27-10
New training manual for treatment of type 1 diabetes in children in developing countries
In collaboration with the International Society for Pediatric and Adolescent Diabetes (ISPAD) Novo Nordisk has today launched a training manual specific to the diagnosis and treatment of diabetes care for children in developing countries. Unveiled on the opening day of the I...
POSTED
10-19-10
African health leaders gather to address significant rise in diabetes
With the incidence of diabetes rising at an alarming rate worldwide, UN member states have resolved to host a summit in 2011 on this growing healthcare threat. In preparation for this, South Africa hosted the Diabetes Leadership Forum Africa 2010 (DLFA) in Johannesburg on 30...
POSTED
05-21-10
Ethics e-learning tools launched by Novo Nordisk and the University of Copenhagen
Thursday 20 May Novo Nordisk and the University of Copenhagen launched two new e-learning tools at the ISO-26000 meeting in Copenhagen. More than 450 delegates from around the globe were invited to test their ethics decision-making skills and to get to know their personal et...
POSTED
02-05-10
Novo Nordisk reports strong financial, social and environmental performance for 2009
Despite continuing challenges in the global economic environment, 2009 was a successful year for Novo Nordisk with solid sales in all business areas, continued improvement in the gross margin and progress in the clinical development pipeline for key projects in both diabetes...
POSTED
02-03-09
Novo Nordisk Launches Fifth Integrated Annual Report Accounting for Financial, Social and Environmental Performance
- February 3, 2009 - Novo Nordisk, the world leader in diabetes care, is pleased to announce its fifth consecutive annual report with the company's financial and non-financial performance in one inclusive document. Novo Nordisk has reported environmental performance for 15 y...